148 related articles for article (PubMed ID: 28631020)
21. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors.
López-Terrada D; Gunaratne PH; Adesina AM; Pulliam J; Hoang DM; Nguyen Y; Mistretta TA; Margolin J; Finegold MJ
Hum Pathol; 2009 Jun; 40(6):783-94. PubMed ID: 19200579
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathological and immunohistochemical study of hepatoblastoma].
Zhang X; Li F; Cheng N
Hua Xi Yi Ke Da Xue Xue Bao; 1998 Sep; 29(3):298-301. PubMed ID: 10684098
[TBL] [Abstract][Full Text] [Related]
23. Hepatoblastoma: the Indiana experience with preoperative chemotherapy for inoperable tumors; clinicopathological considerations.
Heifetz SA; French M; Correa M; Grosfeld JL
Pediatr Pathol Lab Med; 1997; 17(6):857-74. PubMed ID: 9353826
[TBL] [Abstract][Full Text] [Related]
24. The Hippo Effector Transcriptional Coactivator with PDZ-Binding Motif Cooperates with Oncogenic β-Catenin to Induce Hepatoblastoma Development in Mice and Humans.
Zhang S; Zhang J; Evert K; Li X; Liu P; Kiss A; Schaff Z; Ament C; Zhang Y; Serra M; Evert M; Chen N; Xu F; Chen X; Tao J; Calvisi DF; Cigliano A
Am J Pathol; 2020 Jul; 190(7):1397-1413. PubMed ID: 32283103
[TBL] [Abstract][Full Text] [Related]
25. Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma.
Wu JF; Chang HH; Lu MY; Jou ST; Chang KC; Ni YH; Chang MH
J Biomed Sci; 2017 Aug; 24(1):62. PubMed ID: 28851352
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA expression might predict prognosis of epithelial hepatoblastoma.
Gyugos M; Lendvai G; Kenessey I; Schlachter K; Halász J; Nagy P; Garami M; Jakab Z; Schaff Z; Kiss A
Virchows Arch; 2014 Apr; 464(4):419-27. PubMed ID: 24570391
[TBL] [Abstract][Full Text] [Related]
27. Mutant
Crippa S; Ancey PB; Vazquez J; Angelino P; Rougemont AL; Guettier C; Zoete V; Delorenzi M; Michielin O; Meylan E
EMBO Mol Med; 2017 Nov; 9(11):1589-1604. PubMed ID: 28923827
[TBL] [Abstract][Full Text] [Related]
28. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.
Anna CH; Sills RC; Foley JF; Stockton PS; Ton TV; Devereux TR
Cancer Res; 2000 Jun; 60(11):2864-8. PubMed ID: 10850429
[TBL] [Abstract][Full Text] [Related]
29. β-Catenin mutations in 2 nested stromal epithelial tumors of the liver--a neoplasia with defective mesenchymal-epithelial transition.
Assmann G; Kappler R; Zeindl-Eberhart E; Schmid I; Häberle B; Graeb C; Jung A; Müller-Höcker J
Hum Pathol; 2012 Nov; 43(11):1815-27. PubMed ID: 22749188
[TBL] [Abstract][Full Text] [Related]
30. Potential biomarkers for hepatoblastoma: results from the SIOPEL-3 study.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Czauderna P; Sullivan M
Eur J Cancer; 2012 Aug; 48(12):1853-9. PubMed ID: 22137595
[TBL] [Abstract][Full Text] [Related]
31. FOXM1 and CHD4 expression is associated with chemoresistance in hepatoblastoma.
Hino Y; Kohashi K; Tamaki A; Kawakubo N; Hamada H; Fukuhara M; Shibui Y; Tajiri T; Oda Y
Pathol Res Pract; 2024 Jun; 258():155348. PubMed ID: 38761648
[TBL] [Abstract][Full Text] [Related]
32. Hepatoblastomas and liver development: a study of cytokeratin immunoexpression in twenty-nine hepatoblastomas.
Cajaiba MM; Neves JI; Casarotti FF; de Camargo B; ChapChap P; Sredni ST; Soares FA
Pediatr Dev Pathol; 2006; 9(3):196-202. PubMed ID: 16944967
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
Carrillo-Reixach J; Torrens L; Simon-Coma M; Royo L; Domingo-Sàbat M; Abril-Fornaguera J; Akers N; Sala M; Ragull S; Arnal M; Villalmanzo N; Cairo S; Villanueva A; Kappler R; Garrido M; Guerra L; Sábado C; Guillén G; Mallo M; Piñeyro D; Vázquez-Vitali M; Kuchuk O; Mateos ME; Ramírez G; Santamaría ML; Mozo Y; Soriano A; Grotzer M; Branchereau S; de Andoin NG; López-Ibor B; López-Almaraz R; Salinas JA; Torres B; Hernández F; Uriz JJ; Fabre M; Blanco J; Paris C; Bajčiová V; Laureys G; Masnou H; Clos A; Belendez C; Guettier C; Sumoy L; Planas R; Jordà M; Nonell L; Czauderna P; Morland B; Sia D; Losic B; Buendia MA; Sarrias MR; Llovet JM; Armengol C
J Hepatol; 2020 Aug; 73(2):328-341. PubMed ID: 32240714
[TBL] [Abstract][Full Text] [Related]
34. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome.
Weber RG; Pietsch T; von Schweinitz D; Lichter P
Am J Pathol; 2000 Aug; 157(2):571-8. PubMed ID: 10934159
[TBL] [Abstract][Full Text] [Related]
35. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival.
Inagawa S; Itabashi M; Adachi S; Kawamoto T; Hori M; Shimazaki J; Yoshimi F; Fukao K
Clin Cancer Res; 2002 Feb; 8(2):450-6. PubMed ID: 11839663
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic and prognostic value of SALL4 in hepatoblastoma.
Zhou S; Venkatramani R; Gomulia E; Shillingford N; Wang L
Histopathology; 2016 Nov; 69(5):822-830. PubMed ID: 27252091
[TBL] [Abstract][Full Text] [Related]
37. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.
Koch A; Denkhaus D; Albrecht S; Leuschner I; von Schweinitz D; Pietsch T
Cancer Res; 1999 Jan; 59(2):269-73. PubMed ID: 9927029
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
39. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases.
Zynger DL; Gupta A; Luan C; Chou PM; Yang GY; Yang XJ
Hum Pathol; 2008 Feb; 39(2):224-30. PubMed ID: 17949790
[TBL] [Abstract][Full Text] [Related]
40. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
